What are the management options for loss of smell (anosmia) after chemotherapy for testicular cancer?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 2, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Management of Loss of Smell After Chemotherapy for Testicular Cancer

Loss of smell after cisplatin-based chemotherapy for testicular cancer is typically temporary, resolving within 6 months, and requires supportive management with reassurance and monitoring, as no effective treatment exists to reverse chemotherapy-induced olfactory dysfunction. 1

Evidence for Olfactory Changes

The most relevant study directly addressing this issue demonstrates that testicular cancer patients undergoing cisplatin-based chemotherapy experience temporary olfactory threshold score changes 1:

  • Olfactory threshold scores significantly decreased at day 90 post-chemotherapy (8.0 ± 2.51) compared to baseline (10.4 ± 2.20) 1
  • Near-complete recovery occurred by day 180 (9.65 ± 3.26) 1
  • Odor discrimination and identification remained unchanged throughout treatment 1
  • Patients subjectively perceived impaired olfactory function during and immediately after chemotherapy 1

Clinical Management Approach

Immediate Assessment

  • Confirm the symptom is olfactory dysfunction (not taste dysfunction, which often coexists) 2
  • Assess severity and impact on nutrition and quality of life 2
  • Screen for depression, as approximately 25% of patients present with depressed mood at chemotherapy initiation 1

Supportive Management

No effective treatment exists to ameliorate chemotherapy-induced neurotoxic symptoms, including olfactory dysfunction 3. Management focuses on:

  • Reassurance that recovery is expected within 6 months 1
  • Monitor nutritional status, as severe cases can lead to life-threatening weight loss 2
  • For severe parosmia (distorted smell) causing nutrition problems, a simple nose clip during meals can temporarily abolish symptoms and enable oral intake 2

Monitoring Timeline

Based on the recovery pattern observed in testicular cancer patients 1:

  • Day 42: Initial assessment post-chemotherapy
  • Day 90: Expected nadir of olfactory function
  • Day 180: Expected near-complete recovery
  • If symptoms persist beyond 6 months, consider alternative etiologies

Important Caveats

Distinguish from Other Neurotoxicities

While olfactory dysfunction is temporary, other cisplatin-induced neurotoxicities are permanent and irreversible 3:

  • Peripheral sensory paresthesias affect approximately 20% of long-term survivors 3
  • Ototoxicity (tinnitus and hearing loss) is persistent and attributed to cochlear damage 3
  • These permanent neurotoxicities have no effective treatment 3

Rare Severe Presentations

Parosmia (qualitative olfactory distortion) is less common than quantitative loss but can be severe and potentially life-threatening when it causes complete food aversion 2. This requires aggressive nutritional support and the nose clip technique during meals 2.

Long-term Survivorship Considerations

Given the young age of testicular cancer patients and decades of life expectancy post-cure 3, focus follow-up on more serious late effects that impact mortality and morbidity 3:

  • Cardiovascular disease (5-fold increased mortality risk) 3
  • Secondary malignancies (20% cumulative incidence at 35 years) 3
  • Metabolic syndrome and hypogonadism 3
  • Permanent nephrotoxicity and ototoxicity 3, 4

Olfactory dysfunction, while distressing, is self-limited and should not overshadow surveillance for these life-threatening late effects 3.

References

Research

Testicular cancer patients undergoing cisplatin based chemotherapy exhibit temporary olfactory threshold scores changes.

European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2017

Research

Severe chemotherapy-induced parosmia.

American journal of rhinology, 2006

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Long-term effects of chemotherapy in patients with testicular cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1992

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.